Abstract: Disclosed are an anion exchange membrane based on an aromatic polymer functionalized with an imidazolium group, a preparation method thereof, and a vanadium redox flow battery including the membrane.

Abstract: A trisamide compound has the structure of Formula (I) in which R1, R2, and R3 are independently selected from the group consisting of alkyl groups. A polymer composition comprises a trisamide compound of Formula (I) and a polyolefin polymer. The polymer compositions containing a trisamide compound of Formula (I) exhibit very low haze levels and minimal extraction of the trisamide compound.

Abstract: A process of and apparatus for dehydrating an alcohol/water mixture may include pressurizing the mixture to at least 40 psig, heating the pressurized mixture to a temperature of at least 170° F., passing the heated and pressurized mixture through at least one Zeolite separator to produce separate streams of water and pressurized and heated dehydrated alcohol, and using the pressurized and heated dehydrated alcohol to at least in part heat pressurized mixture and to cool the pressurized and heated dehydrated alcohol. At least some implementations may include cooling the pressurized and heated dehydrated alcohol to a temperature below its boiling point at atmospheric pressure. At least some implementations may include applying a vacuum to the water stream side of the Zeolite separator. At least some implementations may include cooling the stream of water to a temperature of less than about 200° F.

Abstract: The present invention relates to processes of preparing N-((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-iso-propyl-1H-pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

Abstract: A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.

Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.

Abstract: The present invention pertains to a process for the cross-ketonization (Piria reaction) between an aryl carboxylic acid and an aliphatic carboxylic acid using a metal-based compound and a slight or a moderate excess of aryl carboxylic acid. A good selectivity, up to 99 mol %, can be achieved. The aryl aliphatic ketone can be used for the preparation of surfactants and other downstream products.

Abstract: Bisphosphite ligands based on benzopinacol, and the use thereof in hydroformylation.

Abstract: The present invention relates to methods for treating cannabis biomass in order to isolate tetrahydrocannabinolic acid (THCA). In another aspect, the present invention relates to a process that involves purification followed by extraction of cannabis biomass to isolate and improve yields of high-purity crystalline extracts.

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

Abstract: A catalyst composition for converting an alcohol to olefins, the catalyst composition comprising the following components: (a) a support (e.g., particles) comprising silicon and oxygen; (b) at least one of copper and silver residing on and/or incorporated into said support; and (c) at least one lanthanide element residing on and/or incorporated into said support. The catalyst may also further include component (d), which is zinc. Also described herein is a method for converting an alcohol to one or more olefinic compounds (an olefin fraction) by contacting the alcohol with a catalyst at a temperature of at least 100° C. and up to 500° C. to result in direct conversion of the alcohol to an olefin fraction containing one or more olefinic compounds containing at least three carbon atoms; wherein ethylene and propylene are produced in a minor proportion of the olefin fraction, and butenes and higher olefins are produced in major proportion.

Abstract: The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

Abstract: Embodiments of the present invention are directed to processes to improve rhodium accountability in continuous liquid recycle hydroformylation processes. In some embodiments, a process comprises contacting in a reaction zone reactants comprising mixed C8 olefins or mixed C9 olefins, hydrogen, and carbon monoxide in the presence of a catalyst comprising rhodium and an organomonophosphite ligand to form a reaction fluid, wherein the reaction fluid is introduced to a strip gas vaporizer to produce a product stream and a vaporizer tails stream, and wherein the vaporizer tails stream comprises at least 1.2 percent by weight C8 internal olefins or at least 1.3 percent by weight C9 internal olefins.

Abstract: This disclosure relates to N-substituted Pd(II)-N-heterocyclic carbene-pyridine complexes, methods of preparing the complexes, and methods of using the complexes in Sonogashira coupling reactions.

Abstract: The invention provides novel quinoline sulfonamide compounds of Formula I: and their use for the treatment or prevention of bacterial infections caused by both Gram positive and Gram negative bacteria such as, for example, infections caused by one or more bacteria from the Enterobactericeae, Staphylococcaceae, or Streptococcaceae families. The compounds described and claimed herein may be formulated in one or more pharmaceutical or veterinary compositions for use in animal husbandry, and in particular in relation to the treatment of mastitis by directly targeting mastitis causing bacteria in a bovine herd. In certain embodiments described herein the pharmaceutical or veterinary compositions are formulated as a spray for direct administration to the udder of the bovine animal such as a cow.

Abstract: Provided is a method with which an ?-allylated cycloalkanone is obtained from a macroyclic compound used as a starting material. The method is a method for producing an ?-allylated cycloalkanone represented by General Formula (IV), and the method includes a step of reacting a compound represented by General Formula (I) and/or a compound represented by General Formula (II) with a compound represented by General Formula (III) in the presence of an acid catalyst to produce an ?-allylated cycloalkanone represented by General Formula (IV), the acid catalyst including an acid catalyst that includes an ammonium cation and an anion.

Abstract: The organic small molecule 4,4?,4?,4??-(5,5-dimethoxycyclopenta-1,3-diene-1,2,3,4-tetrayl)tetrakis(N,N-bis(4-methoxyhenyl)aniline (CPDA 1), shows electrochemical properties very close to spiro-OMeTAD indicating a high compatibility with PSC systems for its use as a hole transport material (HTM). The implementation of the cyclopentadiene dimethyl acetale core helps to red shift the absorption onset of the films as well as provide a flexible spatial configuration of the molecule, which is essential for optimum film forming properties. Transient and steady state emission analysis as well as hole mobility measurements indicate that the new HTM allows a better charge extraction, transport and separation than the spiro-OMeTAD reference compound. PSCs based on the new CPDA 1 show a PCE close to 23% with lower hysteresis than its analogue. Stability studies performed under ambient, heated and humid conditions all showed that CPDA 1 is over-performing spiro-OMeTAD.

Abstract: A process for producing branched alcohols through isomerization, hydroformylation and hydrogenation.

Abstract: A preparation method of 1-(4-aminophenyl)cyclopentanecarbonitrile includes the following steps: step 1: in the presence of Li2CuCl4, adding a nitrochlorobenzene-zinc reagent dropwise to a 1-chlorocyclopentanecarbonitrile solution to prepare a compound 1-(4-nitrophenyl)cyclopentanecarbonitrile; and step 2: subjecting the compound 1-(4-nitrophenyl)cyclopentanecarbonitrile obtained in step 1 to a nitroreduction reaction under the action of a catalyst to prepare the compound 1-(4-aminophenyl)cyclopentanecarbonitrile. The preparation method involves cheap and easily-available raw materials, mild reaction conditions, and convenient operations, leads to high yield, and is environmentally-friendly and suitable for industrial large-scale production.

Abstract: New diphosphites based on cis-butene-1,4-diol.